[go: up one dir, main page]

AR114069A1 - CONSTRUCTION OF A BI-SPECIFIC ANTIBODY AIMED AT MUC17 AND CD3 - Google Patents

CONSTRUCTION OF A BI-SPECIFIC ANTIBODY AIMED AT MUC17 AND CD3

Info

Publication number
AR114069A1
AR114069A1 ARP180103910A ARP180103910A AR114069A1 AR 114069 A1 AR114069 A1 AR 114069A1 AR P180103910 A ARP180103910 A AR P180103910A AR P180103910 A ARP180103910 A AR P180103910A AR 114069 A1 AR114069 A1 AR 114069A1
Authority
AR
Argentina
Prior art keywords
muc17
construction
specific antibody
domain
polynucleotide
Prior art date
Application number
ARP180103910A
Other languages
Spanish (es)
Inventor
Joachim Wahl
Elisabeth Nahrwold
Claudia Bluemel
Jochen Pendzialek
Julie Bailis
Irwin Chen
Christoph Dahlhoff
Sandra Ross
Tobias Raum
Tara Arvedson
Original Assignee
Amgen Inc
Amgen Res Munich Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc, Amgen Res Munich Gmbh filed Critical Amgen Inc
Publication of AR114069A1 publication Critical patent/AR114069A1/en

Links

Landscapes

  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Construcciones de anticuerpos biespecíficos que comprenden un primer dominio que se une a MUC17, un segundo dominio que se une a un epitope extracelular de la cadena CD3e de humano y de Macaca y opcionalmente un tercer dominio, que es una Fc específica. Además, provee un polinucleótido, que codifica la construcción de anticuerpo, un vector que comprende a dicho polinucleótido, células huésped que expresan la construcción y una composición farmacéutica que lo comprende.Bispecific antibody constructs comprising a first domain that binds to MUC17, a second domain that binds to an extracellular epitope of the human and Macaca CD3e chain, and optionally a third domain, which is a specific Fc. Furthermore, it provides a polynucleotide, which encodes the antibody construct, a vector comprising said polynucleotide, host cells that express the construct, and a pharmaceutical composition comprising it.

ARP180103910A 2017-12-29 2018-12-28 CONSTRUCTION OF A BI-SPECIFIC ANTIBODY AIMED AT MUC17 AND CD3 AR114069A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762612242P 2017-12-29 2017-12-29
US202062687063P 2020-06-19 2020-06-19

Publications (1)

Publication Number Publication Date
AR114069A1 true AR114069A1 (en) 2020-07-15

Family

ID=71842931

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180103910A AR114069A1 (en) 2017-12-29 2018-12-28 CONSTRUCTION OF A BI-SPECIFIC ANTIBODY AIMED AT MUC17 AND CD3

Country Status (1)

Country Link
AR (1) AR114069A1 (en)

Similar Documents

Publication Publication Date Title
CL2023001082A1 (en) Bispecific antibody constructs that bind to t cells
UY38041A (en) CONSTRUCTION OF BIESPECFIC ANTIBODY DIRECTED TO MUC17 AND CD3
AR107582A1 (en) BISPECIFIC ANTIBODY CONSTRUCTS FOR PSMA AND CD3 THAT ARE LINKED TO T-CELLS
CR20180420A (en) BIESPECTIFIC ANTIBODY CONSTRUCTS FOR BCMA AND CD3 THAT ARE LINKED TO T-CELLS
CL2018000263A1 (en) Bispecific antibody constructs that bind to egfrviii and cd3.
PE20181152A1 (en) BI-SPECIFIC ANTIBODY CONSTRUCTS THAT JOIN DLL3 AND CD3
AR114069A1 (en) CONSTRUCTION OF A BI-SPECIFIC ANTIBODY AIMED AT MUC17 AND CD3
EA202091600A1 (en) BASIC ANTIBODY DESIGN AIMED AT MUC17 AND CD3